BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Free cash flow 2016–2023
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$20.5MFY2023 · since FY2016: -$6.0M → -$20.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -$20.5M | -5.8% |
| FY2022 | -$19.3M | +27.2% |
| FY2021 | -$26.6M | +25.2% |
| FY2020 | -$35.6M | -203.5% |
| FY2019 | -$11.7M | +8.1% |
| FY2018 | -$12.8M | -401.5% |
| FY2017 | -$2.5M | +57.3% |
| FY2016 | -$6.0M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More BCLI financial trends
BCLI RevenueBCLI Net incomeBCLI Net marginBCLI Gross profitBCLI Gross marginBCLI Operating incomeBCLI Operating marginBCLI Operating cash flowBCLI Capital expendituresBCLI Return on equityBCLI Stock buybacksBCLI Dividends paidBCLI Total assetsBCLI Total liabilitiesBCLI Shareholders’ equityBCLI overview →